Amgen, Inc. (AMGN) Announces Revenue Growth And Profitability In The Second Quarter

Amgen, Inc. (NASDAQ:AMGN) announced its second quarter financial results on July 29, 2014. Amgen’s total revenues increased by 11% on the year to $5.18 billion. Enbrel, Kyprolis, Prolia and XGEVA are the strongest performers among the Amgen, Inc. (NASDAQ:AMGN) brands during the second quarter.

Amgen, Inc. (NASDAQ:AMGN)

Adjusted EPS of Amgen went up by an annual 25% to $2.37, with the help of the higher revenues and increasing  profitability of ENBREL. Adjusted net income appreciated by 26% to $1.82 billion. Amgen, Inc. (NASDAQ:AMGN)’s generation of cash flow was $2.1 billion in the second quarter of 2014 in comparison with $1.4 billion in the second quarter of 2013.

“Robust growth through the first half of 2014 affirms the underlying strength of our business. We are making excellent progress in advancing our pipeline as we prepare to launch a number of promising new innovative medicines. From a position of strength, we have announced today restructuring initiatives that will allow us to reallocate resources to invest in our upcoming launches and drive growth,” Robert A. Bradway, Amgen, Inc. (NASDAQ:AMGN)’s chairman & chief executive officer, said in a statement.

Amgen, Inc. (NASDAQ:AMGN) is one of the leading biotechnology companies, which engages in the discovery, development, manufacturing, and delivery of the human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Shares of Amgen recently traded at $123.31 with a trailing price to earnings of 20.02 and a forward price to earnings of 14.08. Amgen has a 2.00% dividend yield and has gained 13.87% during the past 12 months. The stock has a market cap of $93 billion and total debt/equity ratio of 1.4. Amgen had an average annual EPS growth rate of 11.23% during the last five years. Around 5.1% of the Amgen, Inc. (NASDAQ:AMGN) shares held by insiders and 77.9% of the shares held by institutions.

 Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!